Pertuzumab (Perjeta) — Clinical FAQs

Q: Is Pertuzumab safe during pregnancy?

Pertuzumab pregnancy safety: Embryo-fetal Toxicity — Pertuzumab causes embryo-fetal death and severe developmental defects. Females of reproductive potential must use effective contraception during treatment and for 7 months after the final dose. Exposures during pregnancy must be reported to Genentech (1-888-835-2555) and the FDA MedWatch program.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Question 1

What is Pertuzumab FDA-approved to treat?

Accepted Answer

Pertuzumab is FDA-approved for the following oncology indications: 1. Neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (tumor >2 cm or node-positive) — in combination with trastuzumab and chemotherapy as part of a complete treatment regimen for early breast cancer 2. Adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence — in combination with trastuzumab and chemotherapy 3. First-line treatment of adults with HER2-positive metastatic breast cancer — in combination with trastuzumab and docetaxel (CLEOPATRA trial).

Question 2

How does Pertuzumab work (mechanism of action)?

Accepted Answer

Pertuzumab is a recombinant humanized IgG1κ monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of HER2/ErbB2 — a distinct, non-overlapping epitope from trastuzumab, which binds subdomain IV. By occupying the HER2 dimerization arm, pertuzumab sterically blocks HER2 from forming heterodimers with other HER family receptors, most critically HER3 (ErbB3) and HER1 (EGFR), preventing ligand-driven receptor activation and downstream signaling through PI3K/AKT/mTOR and RAS/MAPK pathways. This mechanism is complementary and synergistic with trastuzumab, which suppresses constitutive HER2 signaling, promotes receptor internalization and downregulation, inhibits proteolytic p95-HER2 shedding, and mediates ADCC. Dual HER2 blockade achieves substantially more comprehensive HER2 pathway suppression than either agent alone. Pertuzumab independently mediates ADCC and antibody-dependent cellular phagocytosis (ADCP) via engagement of effector immune cells through its Fc region.

Question 3

How is Pertuzumab administered?

Accepted Answer

Pertuzumab is administered Intravenous (IV). Administer as intravenous infusion only — never as IV push or bolus.

Question 4

What are the most common side effects of Pertuzumab?

Accepted Answer

The most commonly reported side effects of Pertuzumab (≥10% incidence) include: Diarrhea (46–67%; most common toxicity; Grade 3 in ~8–11%), Nausea, Fatigue / asthenia, Alopecia (with taxane combinations), Peripheral neuropathy (with taxane combinations) and others (14 total). Consult your oncologist for complete prescribing information.

Question 5

Does Pertuzumab have a black box warning?

Accepted Answer

Yes. Pertuzumab carries FDA black box warning(s) regarding: 1. Embryo-fetal toxicity: Pertuzumab can cause embryo-fetal death and severe birth defects (oligohydramnios sequence: pulmonary hypoplasia, skeletal malformations, neonatal death) when administered during pregnancy. Verify pregnancy status before initiating. Advise females of reproductive potential to use effective contraception during treatment and for 7 months after the last dose. Report exposures during pregnancy to Genentech (1-888-835-2555). 2. Left ventricular dysfunction: Pertuzumab can cause subclinical and clinical cardiac failure. Assess LVEF before initiating and at regular intervals. Withhold pertuzumab and trastuzumab for LVEF <40% or for LVEF 40–45% with ≥10 percentage-point decline from baseline persisting after 3-week re-evaluation. Permanently discontinue if LVEF does not recover within 3 weeks of withholding.

Question 6

Is Pertuzumab safe during pregnancy?

Accepted Answer

Pertuzumab pregnancy safety: Embryo-fetal Toxicity — Pertuzumab causes embryo-fetal death and severe developmental defects. Females of reproductive potential must use effective contraception during treatment and for 7 months after the final dose. Exposures during pregnancy must be reported to Genentech (1-888-835-2555) and the FDA MedWatch program.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Pertuzumab — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms